Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report

RATIONALE: Pembrolizumab, an immune-checkpoint inhibitor (ICI), has been shown to be effective for treatment-naive patients with non–small cell lung cancer (NSCLC) and high expression of programmed death-ligand 1 (PD-L1). Therefore, treatment regimens containing pembrolizumab have become a standard...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Medicine (Baltimore)
Prif Awduron: Yamasaki, Masahiro, Funaishi, Kunihiko, Kawamoto, Kazuma, Matsumoto, Yu, Matsumoto, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki, Hattori, Noboru
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wolters Kluwer Health 2019
Pynciau:
5700
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831270/
https://ncbi.nlm.nih.gov/pubmed/31415404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000016834
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg